For bullish biotech investors looking for a way to play the sector well into 2021, today’s article highlights an ETF to consider for that purpose, one which seeks to replicate an index “intended to track the overall performance of companies involved in the development and production, marketing, and sales of drugs based on genetic analysis and diagnostic equipment.” For more on this ETF and its growth potential, CLICK HERE.